We found that patient-derived xenografts of prostate tumors overexpress TRIB2 when the mice were treated with enzalutamide at 30 mg/kg/day for 6 weeks (Fig. 1, G and H). This evidence concerns the gene TRIB2 and prostate neoplasm.